“A Cost-Effectiveness Analysis of Sotorasib As Second-Line Treatment for Patients With KRAS-G12C-Mutated Metastatic Non-Small Cell Lung Cancer (mNSCLC) in Switzerland”. Swiss Medical Weekly, vol. 155, no. 1, Jan. 2025, p. 3777, https://doi.org/10.57187/s.3777.